Full text
Earnings transcript
Read the complete earnings call transcript.
ADCT
ADC Therapeutics S.A.
$1.1
0.12
(12.51%)
| Exchange: | NYSE |
| Market Cap: | 139.91M |
| Shares Outstanding: | 58.854M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Ameet Mallik | |||||
| Full Time Employees: | 263 | |||||
| Address: |
| |||||
| Website: | https://www.adctherapeutics.com |
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company’s pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors. The company maintains strategic collaboration and license agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. Founded in 2011, ADC Therapeutics S.A. has its headquarters located in Epalinges, Switzerland.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 69,558 | 70,837 | 81,357 |
| Gross Profit | 67,029 | 64,888 | 73,683 |
| EBITDA | -145,827 | -102,649 | -106,503 |
| Operating Income | -165,986 | -130,654 | -108,379 |
| Net Income | -240,053 | -157,846 | -142,623 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 354,782 | 321,980 | 323,150 |
| Total Liabilities | 503,031 | 524,622 | 508,984 |
| Total Stockholders Equity | -148,249 | -202,642 | -185,834 |
| Total Debt | 124,377 | 122,998 | 439,011 |
| Cash and Cash Equivalents | 278,598 | 250,867 | 261,338 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -118,686 | -123,835 | -141,174 |
| Capital Expenditure | -3,216 | -867 | -264 |
| Free Cash Flow | -121,902 | -124,702 | -141,438 |
| Net Income | -240,053 | -157,846 | -142,623 |
| Net Change in Cash | -47,843 | -27,731 | 10,471 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 380,540.710 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 438,322.748 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 402,849.480 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | -395,636.458 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | -343,481.554 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | -363,617.773 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 62,856.500 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 75,485.743 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 67,732.082 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 559,534.076 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 644,494.813 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 592,336.130 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 0.530 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 0.590 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 0.490 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 2 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Solid Revenue Performance: ADC Therapeutics reported net product revenues of $18.1 million in Q2 2025, reflecting consistent demand for its key product, ZYNLONTA, and demonstrating the company’s ability to generate income in a competitive biopharmaceutical market.
- Clinical Pipeline Progress: The Q2 2025 earnings call highlighted advancements in clinical programs, with a focus on expanding ZYNLONTA’s indications, which could drive future revenue growth if regulatory approvals are achieved.
- Operational Focus: Management’s emphasis on strategic execution during the earnings call suggests a disciplined approach to balancing innovation with financial stability, positioning the company well for long-term growth.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about ADCT valuation
Is ADC Therapeutics S.A. (ADCT) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for ADC Therapeutics S.A. (ADCT) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is ADCT a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ADCT trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is ADCT’s P/E ratio?
You can see ADCT’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for ADCT?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is ADCT a good long-term investment?
Whether ADCT fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
ADCT
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
12.51
Trading Metrics:
| Open: | 0.97 | Previous Close: | 0.98 | |
| Day Low: | 0.97 | Day High: | 1.16 | |
| Year Low: | 0.78 | Year High: | 4.98 | |
| Price Avg 50: | 3.52 | Price Avg 200: | 3.8 | |
| Volume: | 8.576M | Average Volume: | 990022 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeADCT full analysis
Welcome to MARKETSNAP’s SWOT analysis for ADC Therapeutics! If you’re a long-term investor looking to dive into the biotech space, you’ve probably come across this name, but let’s unpack what makes this company tick and whether it’s a potential gem for your portfolio. Today, we’re breaking down the strengths, weaknesses, opportunities, and threats for ADC Therapeutics, a player in the biotech industry focused on developing targeted cancer therapies. Stick around as we dig into their recent performance, financials, and what…
